Top

Osteoporosis International

Published in:

Open Access 01-01-2019 | Original Article

Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures—a study from the fractures and fall injuries in the elderly cohort (FRAILCO)

Authors: M. Wallander, K. F. Axelsson, D. Lundh, M. Lorentzon

Published in: Osteoporosis International | Issue 1/2019

Abstract

Summary

Osteoporosis is a common complication of androgen deprivation therapy (ADT). In this large Swedish cohort study consisting of a total of nearly 180,000 older men, we found that those with prostate cancer and ADT have a significantly increased risk of future osteoporotic fractures.

Introduction

Androgen deprivation therapy (ADT) in patients with prostate cancer is associated to increased risk of fractures. In this study, we investigated the relationship between ADT in patients with prostate cancer and the risk of incident fractures and non-skeletal fall injuries both compared to those without ADT and compared to patients without prostate cancer.

Methods

We included 179,744 men (79.1 ± 7.9 years (mean ± SD)) from the Swedish registry to which national directories were linked in order to study associations regarding fractures, fall injuries, morbidity, mortality and medications. We identified 159,662 men without prostate cancer, 6954 with prostate cancer and current ADT and 13,128 men with prostate cancer without ADT. During a follow-up of approximately 270,300 patient-years, we identified 10,916 incident fractures including 4860 hip fractures.

Results

In multivariable Cox regression analyses and compared to men without prostate cancer, those with prostate cancer and ADT had increased risk of any fracture (HR 95% CI 1.40 (1.28–1.53)), hip fracture (1.38 (1.20–1.58)) and MOF (1.44 (1.28–1.61)) but not of non-skeletal fall injury (1.01 (0.90–1.13)). Patients with prostate cancer without ADT did not have increased risk of any fracture (0.97 (0.90–1.05)), hip fracture (0.95 (0.84–1.07)), MOF (1.01 (0.92–1.12)) and had decreased risk of non-skeletal fall injury (0.84 (0.77–0.92)).

Conclusions

Patients with prostate cancer and ADT is a fragile patient group with substantially increased risk of osteoporotic fractures both compared to patients without prostate cancer and compared to those with prostate cancer without ADT. We believe that this must be taken in consideration in all patients with prostate cancer already at the initiation of ADT.

Jennings LA, Auerbach AD, Maselli J, Pekow PS, Lindenauer PK, Lee SJ (2010) Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture. J Am Geriatr Soc 58(4):650–657. https://doi.org/10.1111/j.1532-5415.2010.02769.x CrossRefPubMedPubMedCentral

Feldstein AC, Elmer PJ, Nichols GA, Herson M (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 16(12):2168–2174. https://doi.org/10.1007/s00198-005-2016-z CrossRefPubMed

Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22(6):781–788. https://doi.org/10.1359/jbmr.070315 CrossRefPubMed

Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16(2):134–141. https://doi.org/10.1007/s00198-004-1680-8 CrossRefPubMed

Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20(10):1633–1650. https://doi.org/10.1007/s00198-009-0920-3 CrossRefPubMed

Gunderson K, Wang CY, Wang R (2011) Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans. Cancer Epidemiol 35(4):320–327. https://doi.org/10.1016/j.canep.2010.11.007 CrossRefPubMed

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027 CrossRefPubMed

Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103(8):1615–1624. https://doi.org/10.1002/cncr.20955 CrossRefPubMed

Khosla S, Melton LJ 3rd, Riggs BL (2002) Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 87(4):1443–1450. https://doi.org/10.1210/jcem.87.4.8417 CrossRefPubMed

10.

Bilezikian JP (1999) Osteoporosis in men. J Clin Endocrinol Metab 84(10):3431–3434. https://doi.org/10.1210/jcem.84.10.6060 CrossRefPubMed

11.

Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR (2014) Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine 45(3):370–381. https://doi.org/10.1007/s12020-013-0083-z CrossRefPubMed

12.

Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87(8):3656–3661. https://doi.org/10.1210/jcem.87.8.8782 CrossRefPubMed

13.

Townsend MF, Sanders WH, Northway RO, Graham SD Jr (1997) Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79(3):545–550CrossRefPubMed

14.

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154–164. https://doi.org/10.1056/NEJMoa041943 CrossRefPubMed

15.

Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175(1):136–139; discussion 139. https://doi.org/10.1016/s0022-5347(05)00033-9 CrossRefPubMed

16.

Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918–923. https://doi.org/10.1016/j.juro.2010.04.068 CrossRefPubMed

17.

Melton LJ III, Lieber MM, Atkinson EJ, Achenbach SJ, Zincke H, Therneau TM, Khosla S (2011) Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res 26(8):1808–1815. https://doi.org/10.1002/jbmr.405 CrossRefPubMed

18.

Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M (2001) Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166(5):1724–1728CrossRefPubMed

19.

Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395–2411. https://doi.org/10.1007/s00198-011-1713-z CrossRefPubMed

20.

Axelsson KF, Wallander M, Johansson H, Lundh D, Lorentzon M (2017) Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med 282(6):546–559. https://doi.org/10.1111/joim.12678 CrossRefPubMed

21.

Wallander M, Axelsson K, Nilsson AG, Lundh D, Lorentzon M (2016) Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly - a study from the fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res 32:449–460. https://doi.org/10.1002/jbmr.3002 CrossRefPubMed

22.

Axelsson KF, Nilsson AG, Wedel H, Lundh D, Lorentzon M (2017) Association between alendronate use and hip fracture risk in older patients using oral prednisolone. Jama 318(2):146–155. https://doi.org/10.1001/jama.2017.8040 CrossRefPubMedPubMedCentral

23.

Edvinsson J, Rahm M, Trinks A, Hoglund PJ (2015) Senior alert: a quality registry to support a standardized, structured, and systematic preventive care process for older adults. Qual Manag Health Care 24(2):96–101. https://doi.org/10.1097/QMH.0000000000000058 CrossRefPubMed

24.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

25.

Kallman U, Lindgren M (2014) Predictive validity of 4 risk assessment scales for prediction of pressure ulcer development in a hospital setting. Adv Skin Wound Care 27(2):70–76. https://doi.org/10.1097/01.asw.0000439059.72199.41 CrossRefPubMed

26.

Albertsson-Wikland K, Martensson A, Savendahl L, Niklasson A, Bang P, Dahlgren J, Gustafsson J, Kristrom B, Norgren S, Pehrsson NG, Oden A (2016) Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab 101(5):2149–2159. https://doi.org/10.1210/jc.2015-3951 CrossRefPubMed

27.

Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407–S413. https://doi.org/10.1007/s00198-010-1253-y CrossRefPubMed

28.

Wadhwa VK, Weston R, Mistry R, Parr NJ (2009) Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104(6):800–805. https://doi.org/10.1111/j.1464-410X.2009.08483.x CrossRefPubMed

29.

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https://doi.org/10.1007/s11657-013-0136-1 CrossRefPubMedPubMedCentral

30.

Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16(2):222–228. https://doi.org/10.1007/s00198-004-1686-2 CrossRefPubMed

31.

Van Hemelrijck M, Garmo H, Michaelsson K, Thorstenson A, Akre O, Stattin P, Holmberg L, Adolfsson J (2013) Mortality following hip fracture in men with prostate cancer. PLoS One 8(9):e74492. https://doi.org/10.1371/journal.pone.0074492 CrossRefPubMedPubMedCentral

32.

Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C (2012) Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 30(26):3271–3276. https://doi.org/10.1200/jco.2011.38.8850 CrossRefPubMedPubMedCentral

33.

Quality and Efficiency in Swedish Health Care - Regional Comparisons 2013 by the Swedish Association of Local Authorities and Regions.

34.

Poon Y, Pechlivanoglou P, Alibhai SMH, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M (2018) Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures. BJU Int 121(1):17–28. https://doi.org/10.1111/bju.14015 CrossRefPubMed

35.

Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755. https://doi.org/10.1056/NEJMoa0809003 CrossRefPubMedPubMedCentral

Title: Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures—a study from the fractures and fall injuries in the elderly cohort (FRAILCO)
Authors: M. Wallander
K. F. Axelsson
D. Lundh
M. Lorentzon
Publication date: 01-01-2019
Publisher: Springer London
Published in: Osteoporosis International / Issue 1/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-018-4722-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures—a study from the fractures and fall injuries in the elderly cohort (FRAILCO)

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Lean mass and lower limb muscle function in relation to hip strength, geometry and fracture risk indices in community-dwelling older women

Osteoporosis prevention: where are the barriers to improvement in a French general population? A qualitative study

Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial

Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study

Impact of mild and moderate/severe vertebral fractures on physical activity: a prospective study of older women in the UK

Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations